FT News Briefing
Australia vaccine funding, Sinopharm’s global push, ECB accelerates stimulus
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Canberra is contemplating investing in a A$1bn biopharmaceutical plant to reduce its dependence on imports of critical medicines, China’s state-backed pharmaceutical group, Sinopharm, wants more governments to buy its Covid-19 vaccine, and Spain is set to become the first EU country to amend its laws to give some gig economy workers employee rights. Plus, the FT’s markets editor, Katie Martin, explains why the European Central Bank will accelerate its bond buying programme.
Australia considers funding vaccine maker to curb reliance on imports
https://www.ft.com/content/483e6275-6d27-433c-9cbc-6918f2c916c6?edit=true
Spain to grant gig delivery workers employee rights
https://www.ft.com/content/73be294b-a43d-4387-aced-7b5cb0d91007?
Sinopharm faces battle to turn Covid vaccine into a global success
https://www.ft.com/content/99c7a9de-fc11-45ab-890b-f6733ccb4186
ECB pledges to step up pace of stimulus to counter market sell-off
https://www.ft.com/content/bd7ccf1d-3b07-4f13-9a14-68692ef84e95
Rise of the retail army: the amateur traders transforming markets
https://www.ft.com/content/7a91e3ea-b9ec-4611-9a03-a8dd3b8bddb5
Hosted on Acast. See acast.com/privacy for more information.